# Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

> **NCT03405272** · PHASE2 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Recombinant Anti-EGFR Monoclonal Antibody（SCT200）

## Key facts

- **NCT ID:** NCT03405272
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-12
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405272, "Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03405272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*